Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma.

Histopathology - 1 Aug 2020

Chen Tiffany Y, Lorch Jochen H, Wong Kristine S, Barletta Justine A

Abstract excerpt

AIMS: Treatment with a BRAF inhibitor, alone or in combination with a MEK inhibitor, may be considered for BRAF-mutant anaplastic thyroid carcinoma (ATC). The purpose of this study was to characterise the histology of BRAF V600E-mutant ATC. METHODS AND RESULTS: We identified 28 ATC that were consecutively resected between 2003 and 2019. All tumour slides for each case were evaluated for the presence of a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Hepatocellular
Share to Diagnosis, Differential

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunohistochemistry

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Carcinoma, Anaplastic

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 32428249
DOI: 10.1111/his.14144

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma.PMID 32428249Read ↗

Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement.Semantic proximity Read ↗

Recent advances in anaplastic thyroid cancer management.Semantic proximity Read ↗

Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.Semantic proximity Read ↗

Evolving Pathology of Anaplastic Thyroid Carcinoma: Integrating Morphology, Immunohistochemistry, and Molecular Insights.Semantic proximity Read ↗

Histopathologic Features and Clinical Outcome of Anaplastic Thyroid Carcinoma with a Minor Anaplastic Component.Semantic proximity Read ↗

Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.Semantic proximity Read ↗

Combination therapy with BRAF and MEK inhibitors for anaplastic thyroid cancer: A report of two cases.Semantic proximity Read ↗

Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.Semantic proximity Read ↗

Primary squamous cell carcinoma of thyroid with a novel BRAF mutation and High PDL-1 expression: A case report with treatment implications and review of literature.Semantic proximity Read ↗

Pathologic Features Associated With Molecular Subtypes of Well-Differentiated Thyroid Cancer.Semantic proximity Read ↗

Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma.Semantic proximity Read ↗

Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.